Download PDF
Thromb Haemost 2014; 112(02): 223
DOI: 10.1160/TH14-07-0583
T&H Insights
Schattauer GmbH

CD40-CD40L: a Janus-faced interaction

Esther Lutgens
1   Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilians University (LMU), Munich, Germany
2   Dept of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received: 04 July 2014

Accepted: 04 July 2014

Publication Date:
04 December 2017 (online)

Also available at
    Permissions and Reprints

See also:

Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in miceThromb Haemost 2014; 112(08): 379-389
DOI: 10.1160/TH13-08-0653

Insight on ► Willecke et al. Thromb Haemost 2014; 112: 379-389.

 

  • References

  • 1 Engel D, Seijkens T, Poggi M. et al. The immunobiologiy of CD154-CD40-TRAF interactions in atherosclerosis. Semin Immunol 2009; 21: 308-312.
    CrossrefPubMedSearch in Google Scholar
  • 2 Wolf D, Hohmann JD, Wiedemann A. et al. Binding of CD40L to Mac-1’s I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice. Circ Res 2011; 109: 1269-1279.
    CrossrefPubMedSearch in Google Scholar
  • 3 Lutgens E, Lievens D, Beckers L. et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207: 391-404.
    CrossrefPubMedSearch in Google Scholar
  • 4 Willecke F, Tiwari S, Rupprecht B. et al. Interruption of classic CD40L–CD40 signalling but not of the novel CD40L–Mac-1 interaction limits arterial neointima formation in mice. Thromb Haemost 2014; 112: 379-389.
    Thieme ConnectPubMedSearch in Google Scholar